LPA disruption with AAV-CRISPR potently lowers plasma apo(a) in transgenic mouse model: A proof-of-concept study-Reference-Cited by-同舟云学术

LPA disruption with AAV-CRISPR potently lowers plasma apo(a) in transgenic mouse model: A proof-of-concept study

Published:2022-12 Issue: Volume:27 Page:337-351
ISSN:2329-0501
Container-title:Molecular Therapy - Methods & Clinical Development
language:en
Short-container-title:Molecular Therapy - Methods & Clinical Development

Author:

Doerfler Alexandria M.,Park So Hyun,Assini Julia M.,Youssef Amer,Saxena Lavanya,Yaseen Adam B.,De Giorgi Marco,Chuecos Marcel,Hurley Ayrea E.,Li Ang,Marcovina Santica M.,Bao Gang,Boffa Michael B.,Koschinsky Marlys L.,Lagor William R.^ORCID

Publisher

Elsevier BV

Subject

Genetics,Molecular Biology,Molecular Medicine

Reference54 articles.

1. A new serum type in man- the Lp system;Berg;Acta Pathol. Microbiol. Scand.,1963

2. Lp(a) lipoprotein and pre-β1-lipoprotein in patients with coronary heart disease;Berg;Clin. Genet.,1974

3. Epidemiology of Lp(a) lipoprotein: its role in atherosclerotic/thrombotic disease;Djurovic;Clin. Genet.,1997

4. Lipoprotein(a) concentration and the risk of coronary heart disease, Stroke, and nonvascular mortality the emerging risk factors collaboration ∗ Europe PMC funders group;Erqou;JAMA,2009

5. Apolipoprotein(a) isoforms and the risk of vascular disease. Systematic review of 40 studies involving 58, 000 participants;Erqou;J. Am. Coll. Cardiol.,2010

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in Omics and Breakthrough Gene Therapies: A Glimpse into the Future of Peripheral Artery Disease;Annals of Vascular Surgery;2024-10

2. Advances in nucleic acid-targeted therapies for cardiovascular disease prevention;Cardiovascular Research;2024-07

3. New insights into the therapeutic options to lower lipoprotein(a);European Journal of Clinical Investigation;2024-05-22

4. Should we already deal with lipoprotein(a) in clinical practice?;Vnitřní lékařství;2024-05-06

5. Emerging therapies for refractory hypercholesterolemia: a narrative review;Future Cardiology;2024-04-25